The Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraine

Basit Öğe Kaydı
dc.contributor.authorSirin, Tuba Cerrahoglu
dc.contributor.authorAcarer, Ahmet
dc.contributor.authorSirin, Hadiye
dc.date.accessioned2019-10-27T22:29:10Z
dc.date.available2019-10-27T22:29:10Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: Resistant chronic migraine (RCM) causes a considerable decline in the quality of life and work efficiency of the patients and ultimately might even decrease their socioeconomic level because of severe and permanent headaches. In addition, migraine attacks force patients to rush to the emergency rooms, which leads to overcrowding and exhaustion of medical resources. In this study, the effect of onabotulinum toxin A (OBoNT-A) treatment was assessed in terms of efficiency and the quality of life retrospectively at patients with RCM. Method: 15 patients with RCM who were given 155 IU OBoNT-A treatment twice in 12 weeks have been studied retrospectively in terms of change of headache frequency, severity, and the health related quality of life scores (physical function, physical restriction, pain, general health, vitality, social function, emotion and mental health categories) for 24 weeks. Response to treatment is identified as >= 30% decrease in headache frequency while the change in the quality of life was determined with short form-36 before and after treatment. Findings: Average headache frequency was 26.3 day/month before treatment. After 24 weeks, 93% of the patients were responsive to the treatment. After OBoNT-A treatment average headache frequency decreased to 16,6 day/month in 12 weeks and to 17,8 day/month in 24 weeks (p<0.001). Average health related quality of life scores before treatment were under 50%, while all the health related quality of life scores improved after treatment(p<0.001). At the end of 24 weeks, headache severity significantly decreased (p<0.001). Conclusion: OBoNT-A is an effective treatment in patients with RCM and it must be considered a first line treatment for RCM patients considering the cost-effectiveness researches.en_US
dc.identifier.endpage548en_US
dc.identifier.issn1302-1664
dc.identifier.issn1302-1664en_US
dc.identifier.issue3en_US
dc.identifier.startpage539en_US
dc.identifier.urihttps://hdl.handle.net/11454/51056
dc.identifier.volume32en_US
dc.identifier.wosWOS:000365428100008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherJournal Neurological Sciencesen_US
dc.relation.ispartofJournal of Neurological Sciences-Turkishen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOnabotulinum toxin-Aen_US
dc.subjectresistant chronic migraineen_US
dc.subjectquality of lifeen_US
dc.titleThe Effect of Onabotulinum Toxin-A on Frequency of Headache, Severity of Headache and Health Related Life-Quality at Patients With Resistant Chronic Migraineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu